论文部分内容阅读
作者根据干扰素在体外能有效消除细胞培养中甲型肝炎的持续感染。用干扰素治疗3例由甲型肝炎（HA）引起的亚急性暴发性肝功能衰竭（FH）和1例伴有迁延性肝功能衰竭的急性重症甲型肝炎（ASH）患者。 4例患者全部查到抗HA病毒的IgM抗体。3例FH患者在发病10天～8周后发生昏迷,预计预后极差（存活率为33.3％）,1例ASH患者治疗前凝血酶原时间为对照值的40％,并伴有侵袭性坏死性炎性反应的融合性肝坏死。对这些病例用肝支持疗法,未观察到自发性肝功能恢复。在发病19～33天后,用β干扰素治疗,每日1剂,每剂300万U,共应用13～81剂,观察到肝功能明显改善,胆红素含量（μmol/L）在治疗前分别为381、587、150和321,治疗后分别为140、22、15和113;凝血酶原时间（％）治疗前分别分27、32、33和40,治疗后分别为70、76、76和61,4例患者全部存活。
The authors based on interferon in vitro can effectively eliminate the ongoing infection of hepatitis A in cell culture. Interferon was used to treat 3 patients with subacute fulminant hepatic failure (FH) caused by Hepatitis A (HA) and 1 patient with acute severe Hepatitis A (ASH) with persistent liver failure. 4 patients were found anti-HA virus IgM antibodies. Three patients with FH developed coma after 10 days to 8 weeks of onset and predicted a poor prognosis (survival rate of 33.3%). One patient with ASH had 40% of the pre-treatment prothrombin time associated with invasive necrosis Inflammatory reaction of fusion hepatic necrosis. For these cases with liver support therapy, no recovery of spontaneous liver function was observed. After the onset of 19 to 33 days, with interferon beta treatment, a daily dose of 3 million U per dose, a total of 13 to 81 agents were applied, significantly improved liver function was observed, bilirubin content (μmol / L) before treatment Respectively, 381,587,150 and 321, respectively, after treatment were 140,22,15 and 113; prothrombin time (%) before treatment were divided 27,32,33 and 40, respectively, after treatment were 70,76,76 And 61,4 patients all survived.